TLDR New CRISPR/Cas9 variants and nanotechnology-based delivery methods are improving cancer treatment, but choosing the best variant and overcoming certain limitations remain challenges.
The review discusses the recent advancements in genome-editing technology using CRISPR/Cas9 variants and stimuli-responsive targeting approaches within tumor cells. Various CRISPR/Cas9 variants like Sniper-Cas9, eSpCas9 (1.1), SpCas9-HF1, HypaCas9, xCas9, and evoCas9 have been developed to improve genome-editing specificity, but choosing the ideal variant for a specific target sequence remains a challenge. The review also highlights the use of nanotechnology-based stimuli-responsive delivery approaches, such as pH, glutathione (GSH), photo, thermal, and magnetic responsive systems, which enhance cellular internalization and controlled release. Despite the potential of the CRISPR/Cas9 system in cancer management, there are still critical constraints that need to be addressed for clinical translations.View this study on mdpi.com →
Advancements in nanoformulations for CRISPR-Cas9 genome editing can respond to specific triggers for controlled gene editing, showing promise in treating incurable diseases, but challenges like precision and system design complexity still need to be addressed.
Scientists have created a new hair loss treatment using ultrasound to deliver gene-editing particles, which resulted in up to 90% hair regrowth in mice.